INTRODUCTION
Cystic fibrosis (CF) is an autosomal recessive disease caused by mutations in the CF transmembrane conductance regulator (CFTR) gene. The disease affects approximately one in 2500 live births (although this number varies greatly in different populations) and has long been thought of as a Caucasian disease. However, improved awareness and diagnostic tools now lead to increasing numbers of CF patients being diagnosed, for example in the Indian subcontinent (http://www.cfww.org/pub/english/cfwnl/7/617/Cy stic_Fibrosis_in_India, 2016). CF is a multiorgan disease but in the developed world, chronic lung infection and inflammation causes most morbidity and mortality. The median age of survival in the UK patient population is currently $40 years (www.cysticfibrosis.org.uk/media/598466/annualdata-report-2013-jul14.pdf, 2015).
CFTR is best known as a cyclic AMP-dependent chloride channel, which acts in the apical membrane of many epithelial cells throughout the body. However, the protein has several other functions and has also been shown to transport bicarbonate and regulate other ion channels such as the epithelial sodium channel. CFTR, therefore plays an important role in epithelial ion transport and fluid homeostasis.
Several hypotheses have been postulated to explain how mutations in CFTR might cause CF. The 'low-volume' hypothesis postulates that, in addition to a reduction in chloride transport, the lack of functional CFTR also leads to sodium hyperabsorption through disinhibition of epithelial sodium channel, and subsequent increased water absorption into the tissue, leading to reduced airway surface liquid and impaired mucociliary clearance [1] . More recently, it has been suggested that reduced bicarbonate secretion through CFTR alters the pH on the airway surface, which may affect airway defence mechanisms [2] and alters mucus properties [3] .
Approximately, 2000 mutations per gene alterations in the CFTR gene have been described (http://www.genet.sickkids.on.ca/app, 2016) and the 'clinical and functional translation of CFTR (CFTR2)' initiative aims to identify and classify the disease-causing mutations (http://www. cftr2.org, 2016). To date, mutations have been grouped into six classes based on the effect they have on CFTR expression and function. The improved understanding of CF pharmacogenetics has led to licensing of an effective drug (ivacaftor, Kalydeco) that corrects the molecular defect in $4-5% of patients [4] . Correction of the most common F508del mutation which is present in $90% of UK patients is proving more challenging [5 && ]. Trade name of a drug, a combination therapy consisting of two drugs (lumacaftor and ivacaftor) has now been licensed by the FDA (lumacaftor/ivacaftor) but was recently rejected for reimbursement by the UK's National Institute for Health and Care Excellence (NICE) as being 'not cost-effective' because of relatively limited efficacy [6 & ]. Better therapies to treat CF are still required. The older literature related to CF gene therapy has been reviewed in many publications [7] . We will, therefore, restrict this review to a brief description and discussion of the key lessons learnt, and focus on more recent progress in the field.
WHAT HAS HAPPENED IN THE FIELD?
A combination of CF being a single-gene disorder, the comparatively easy, noninvasive access to the lung, the fact that gene therapy does not require detailed information about the patient's genotype or which of the six mutation classes these might belong to, or requires the cause of disease pathophysiology to be conclusively understood, led to unrealistic expectations and hype by academia, industry, and patients in early phases of the programme. However, it quickly became clear that CF gene therapy was considerably more challenging than initially anticipated. To date, we know that compared with some other organs, gene transfer to the lung is inefficient, understanding the strengths and weaknesses of viral and nonviral gene transfer agents (GTAs) and careful selection of these for CF gene therapy is essential, and gene therapy can stabilize CF lung disease (see next paragraph for more details and a list of key milestone studies in Table 1 ).
WHY IS GENE TRANSFER TO THE LUNGS CHALLENGING?
Potent intra and extracellular barriers that have evolved to protect us from viruses, bacteria, and other inhaled particles also defend against uptake
KEY POINTS
The development of CF gene therapy has been slower than anticipated but is now accelerating.
Repeated administration of a nonviral GTA over a 12-month period stabilizes CF lung disease.
A novel lentiviral vector shows promise for CF gene therapy and is progressing into a first-in-man trial. [10] showed that nonviral CFTR cDNA transfer was able to partially correct the chloride transport in tracheal epithelium of CF knockout mice 4. In the same year, Zabner et al. [11] performed the first, albeit small and not placebo-controlled, CF gene therapy trial in three patients. A first-generation adenoviral vector carrying the CFTR cDNA was administered to the nasal epithelium and shown to partially restore cAMP-mediated chloride transport 5. 5 years after cloning of CFTR, Crystal et al. [12] performed the first phase one dose-escalation CF gene therapy study. This was first and foremost a safety study and showed transient inflammatory responses at the highest dose (5 Â 1e9 plaque forming units per patient) 6. 6 years after cloning of CFTR, Caplen et al. [13] provided first evidence that a nonviral gene transfer agent (DC-Chol : DOPE) complexed with CFTR cDNA could partially correct cAMPmediated chloride transport in the nasal epithelium of CF patients 7. 10 years after cloning of CFTR, Alton et al. [14] demonstrated that a nonviral gene transfer agent (GL67A) complexed with a plasmid DNA carrying the CFTR cDNA could partially correct cAMP-mediated chloride transport in the lungs of CF patients of inhaled GTAs. Among the intracellular barriers, the nuclear membrane presents a significant hurdle particularly for nonviral GTAs. Further, there are extracellular barriers, including airway mucus, mucociliary clearance, CF mucopurulent sputum [16] [17] [18] , as well as humoral and cellular immune responses [19] .
WHAT HAS BEEN LEARNT ABOUT STRENGTHS AND WEAKNESSES OF THE DIFFERENT GENE TRANSFER AGENTS?
Vectors that carry nucleic acids into cells fall broadly into two categories: viral and nonviral. Viral vectors are generally considered more efficient because they have evolved to infect cells and, therefore, carry suitable proteins to overcome at least some of the barriers described above. Adenoviruses and adenoassociated viruses (AAVs) have a natural tropism for the lungs and seemed obvious choices for early CF gene therapy trials [7] . However, preexisting and induced immune responses to the viral vector limit their usefulness for the treatment of a life-long disease such as CF. To date, we have not seen convincing evidence in either preclinical models or clinical trials to demonstrate that repeated administration of adenoviral or AAV vectors to immune competent lungs is feasible without loss of efficacy [7] .
In contrast to viral vectors, the simpler structure of nonviral formulations, which generally do not contain proteins, make them less likely to induce immune responses. Between 1999 and 2004, nine CF gene therapy trials used nonviral GTAs [7] . Combined, these studies presented a mixed picture with some reporting detectable vector-specific mRNA and some partial correction of the chloride transport defect, whereas others did not. Proof of concept for efficacy (based on detection of mRNA and partial correction of chloride transport) of repeated administration (three doses delivered to the nasal epithelium) of a nonviral vector was only assessed in one study [20] .
FIRST EVIDENCE OF CLINICALLY-MEANINGFUL OUTCOMES
The UK CF Gene Therapy Consortium was founded in 2001, consisting of the three groups in Edinburgh, London, and Oxford, who had previously conducted CF gene therapy trials. The explicit aim was to share expertise and knowledge in a translational programme to assess whether proof of principle that gene therapy can change the progression of CF lung disease could be demonstrated. The Gene Therapy Consortium recently completed a pivotal phase IIB multidose trial. In brief this included:
(1) An extensive screening programme determined that the cationic lipid formulation GL67A, first used in the 1990s, remained the most potent GTA for airway gene transfer some 2 decades later [21] . (2) Identified the likely cause of mild flu-like symptoms noted in previous single-dose lung trials [14, 22] to be immune-stimulatory HYPERLINK (CpG) dinucleotides used in first-generation plasmids, and removed these. The resulting plasmid, pGM169 has also been codon optimized and contains a novel regulatory element, Hybrid CpG-free CMV enhancer/elongation factor 1 alpha promoter, consisting of the elongation factor 1a promoter coupled to the human Cytomegalovirus (CMV) enhancer, the latter to improve duration [23] . (3) Undertaken regulatory-compliant multidose toxicology studies in mice [24] and sheep [25] supporting progression into a multidose clinical trial. Interestingly, repeated aerosolization of pGM169/GL67A to mice led to cumulative dose-related expression on repeat dosing, reaching 94 AE 19% of endogenous murine CFTR levels after 12 deliveries. These data further supported progression into a multidose clinical trial. (4) Showed that in a single-dose, dose-escalation (5, 10, and 20 ml of pGM169/GL67A) phase I/IIa safety trial that, despite CpG depletion of the plasmid, patients receiving the 10 and 20-ml dose still developed mild flu-like symptoms, including fever [26] . The likely explanation is that both the volume administered to the lung and the lipid also contribute to the inflammatory response (in addition to CpG sequences). The 5-ml dose (containing $12.5 mg plasmid DNA) was chosen for the multidose trial. ]. The treatment was well tolerated, and the trial met its primary endpoint showing a significant, albeit modest, treatment effect in the pGM169/GL67A group versus placebo at 12-month follow-up (3Á7%, 95% confidence interval 0.1-7.3; P ¼ 0.046; Fig. 1a ). Prespecified subgroup analysis showed that patients with more severe lung disease at the start of treatment responded better than patients with milder lung disease at the start of treatment ( Fig. 1b and c) . Reasons for this are currently unknown and various hypotheses have to be tested. One simple explanation may relate to the amount of material deposited in the proximal airways, which is likely higher in patients with more severe lung diseases because of sputum-restricted deposition distally into the smaller airways.
The significant effect on lung function shown for the first time in this trial, and supported by multiple secondary outcome measures, was paralleled by only minimal changes in the ion transport assays and no detectable vector-specific mRNA. This discordance may relate to the timing and sensitivity of the assays, the site of measurement, and/or the relatively small area of airways assessed when using molecular assays and questions the use of these assays as go/no-go decision points in the development of CF gene therapy. Although the trial reached its primary endpoint, the magnitude and variability of the effect does not warrant immediate progression into phase III trials; gene transfer to the lung requires further improvements in efficacy.
ARE THERE FURTHER OPTIONS TO INCREASE LEVELS OF GENE TRANSFER TO THE AIRWAYS?
We have considered increasing the dose of GL67A/ pGM169 or shortening the dosing interval. Alternatively, a more potent nonviral vector could be used, although we are not currently aware of one.
As an alternative strategy, although adenovirus and AAV are unlikely to be suitable for CF gene therapy, lentiviral vectors have recently shown great promise. Integrating vectors possess an inherent risk of inducing insertional mutagenesis but it is important to discriminate between the early g-retroviral vectors that have been shown to cause leukaemia in some patients when used for bone marrow transduction [27] , from the more advanced lentiviral vectors that have not shown evidence of insertional mutagenesis in clinical trials [28] [29] [30] . Lentiviral vectors have no natural lung tropism and, therefore, require pseudotyping with appropriate envelope proteins to facilitate lung gene transfer. The vesicular stomatitis virus G protein is commonly used for pseudotyping lentiviral vectors and works well for bone marrow transduction ex vivo. However, for transduction of airway epithelium, it is necessary to precondition the tissue with detergents, which damage the epithelium and allow access to the basolateral membrane via intercellular spaces [31] . This approach raises safety concerns for translation into clinical trials, particularly in CF patients with bacterial lung infections. As a result, several groups, including ours, have investigated the use of other envelope proteins, including the baculovirus protein GP64 [32] , proteins from Ebola or Marburg filoviruses [33] , the hemagglutinin protein from influenza virus [34] , and the fusion and hemagglutinin-neuraminidase protein from Sendai virus [35] [36] [37] , (Fig. 2) , which are viruses that either have a broad tissue tropism (baculovirus) or a natural tropism for the lung (influenza and Sendai virus). We, and others, have shown that a single dose of lentivirus leads to life-long stable gene expression in the murine lung ($2 years) and that repeated administration of the vector (10 daily doses or three times 1-month doses) is feasible [32, 36, 37] (Fig. 3 ). To date, there has been no report of insertional mutagenesis or other untoward toxicity in lungs of mice. A direct comparison between the lead nonviral vector GL67A, which was used in the recently completed phase IIb CF gene therapy trial (see previous section) and the fusion/ hemagglutinin-neuraminidase-pseudotyped lentiviral vector indicates that the virus is several log orders more efficient in transducing airway epithelial cells, which are the target cells for CF gene therapy.
In addition to the envelope proteins, optimization of promoter/enhancer elements that drive recombinant protein expression require careful optimization. We have recently shown that the hCEF regulatory element, consisting of the elongation factor 1a promoter coupled to the human CMV enhancer, leads to the highest levels of gene expression in murine lungs and human air-liquid interface cultures [38 && ]. 
ARE FURTHER GENE THERAPY TRIALS PLANNED IN THE NEAR FUTURE?
The efficiency, duration of expression, lack of toxicity and, uniquely, efficacy on repeated administration support progression of the fusion/ hemagglutinin-neuraminidase-pseudotyped lentivirus into a clinical trial. The first-in-man trial will be a phase I/IIA single-dose safety study using the nasal epithelium as a surrogate organ to allow easier monitoring of safety and gene expression profiles. Pending an appropriate outcome, this study will rapidly be followed by a lung trial for which parallel improvements in vector production will be required. Lentiviral vectors with other pseudotypes may also be assessed in clinical trials, although we are not aware of any immediate plans for such studies.
ARE THERE OTHER GENETIC MEDICINE-BASED APPROACHES?
In addition to 'classical' gene therapy, mRNA as a template for CFTR gene supplementation has long been appealing as an alternative to DNA-based gene delivery. Specifically, this avoids the rate-limiting step of nuclear entry into nondividing airway epithelial cells, being translated rapidly and efficiently directly in the cytoplasm [39] , and chemical modifications made to enhance efficacy of mRNA therapy have been successful [40] . Proof of concept for the efficacy of repeated pulmonary delivery of chemically modified mRNA has been established in a murine model of surfactant protein B deficiency [41] but because of the comparatively long transcript, development of CFTR mRNA therapy is more complex and has not been reported yet. In addition to gene and mRNA therapy, correction of the genetic defect in the genome (gene editing) or in mRNA (mRNA repair) are being developed. Genome editing using zinc-finger nucleases, Transcription activator-like effector nuclease, or the Clustered regularly interspaced short palindromic repeats/CRISPR associated protein 9 system is revolutionizing research and therapeutic strategies for many diseases. In the context of CF, genome editing has been used to repair CFTR mutations and restore protein function in cell lines [42] , intestinal organoids [43] , and CF patient-derived induced pluripotent cells in vitro [44, 45] . This technology will be very useful for developing mutation-specific cell lines for drug screening but progression into in-vivo gene repair will be difficult [46] , given both the genedelivery hurdles faced by standard gene therapy approaches, as well as the terminally differentiated nature of the respiratory epithelium, not immediately encouraging for gene repair mechanisms.
Different strategies have also been suggested to overcome mutations in the CFTR mRNA. Small molecule drugs such as ataluren, which bypass premature stop mutations, are being assessed in clinical trials and have shown modest improvements in pulmonary function [47] ; a multinational phase III placebo-controlled efficacy trial is currently underway.
Alternative strategies are based on direct repair of the mRNA using short RNA oligonucleotides. Two clinical trials are currently ongoing. PQ-010-001 is a phase Ib study of QR-010 administered via inhalation to adults homozygous for the F508del mutation to evaluate safety and tolerability, pharmacokinetics, and exploratory efficacy endpoints. (NCT02532764: https://clinicaltrials.gov/ct2/show/ NCT02532764?term=ProQR&rank=1). PQ-010-002 is a proof-of-concept study to evaluate the effect of QR-010 on nasal potential difference in adults with CF either homozygous or compound heterozygous for the F508del mutation (NCT02564354: https:// clinicaltrials.gov/ct2/show/NCT02564354?term= ProQR&rank=2).
CONCLUSION
More than 25 years of CF gene therapy have opened our eyes to the strengths and weaknesses of the available viral and nonviral GTA. After a 10-year lull, interest in CF gene therapy is now on an upward slope because of proof of concept that the molecular defect is targetable using small molecule drugs, the successful completion of a nonviral phase IIb multidose trial showing that gene therapy can alter the progression of CF lung disease, and the success of gene therapy in other diseases, including immune deficiencies and haemophilia. However, a number of outstanding questions remain. How much CFTR expression do we need to stabilize or improve CF lung disease and in which cells do we need expression in. Will the CF pig and ferret models be useful for assessing efficacy of gene transfer and form gono-go decision point before progression into clinical trials?
